Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(33.3%)
Phase 1
1(33.3%)
N/A
1(33.3%)
3Total
Phase 3(1)
Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07569640Phase 3Not Yet Recruiting

HFrEF Polypill in Sri Lanka RCT

Role: collaborator

NCT05452447Not ApplicableCompleted

Spatial Repellents for Aedes-borne Virus Control in Sri Lanka

Role: collaborator

NCT06831864Phase 1Completed

Heart Failure With Reduced Ejection Fraction Polypill Implementation Strategy in Sri Lanka

Role: collaborator

All 3 trials loaded